Comparative Pharmacology
Head-to-head clinical analysis: DRYTEC versus PSEUDO 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRYTEC versus PSEUDO 12.
DRYTEC vs PSEUDO-12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drytec is an antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic symptoms.
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
1-2 tablets (paracetamol 500 mg/pseudoephedrine 30 mg) orally every 4-6 hours; maximum 8 tablets per day.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5 to 4 hours in adults with normal renal function; may be prolonged in elderly or patients with renal impairment.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Renal excretion of unchanged drug accounts for approximately 65% of the administered dose; fecal/biliary elimination contributes about 35%.
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Category C
Category C
Decongestant
Decongestant